FOLH1 and neoplasm: Further modifications are needed to improve the binding affinities, pharmacokinetics, and tumor uptake of 68Ga-labeled PSMA/FAP bispecific tracers by considering the linker’s length, lipophilicity, and the use of less lipophilic PSMA- and/or FAP-targeting pharmacophores.